Anti-NRAS (C-terminal) antibody produced in rabbit
SIGMA/SAB4200779 - IgG fraction of antiserum
Synonym: GTPase NRas; Transforming protein N-Ras
Product Type: Chemical
Enhanced Validation-By Recombinant Expression Antibody recognition: Anti-NRAS (C-terminal) antibody produced in Rabbit (Cat. No. SAB4200779) is confirmed by western blot in the cell sample that has been altered to overexpress the target protein-HEK-293T over expressing NRAS (Lane 1) while no staining is detected in the wild type sample-HEK-293T (Lane 2). The antibody was developed with Goat Anti-Rabbit IgG, Peroxidase conjugate (Cat. No. A0545) and a chemiluminescent substrate. Antibody dilution: 1:2,000.
Western Blotting Ras family protein specificity test: 1:2,000 dilution of Anti-NRAS (C-terminal) antibody produced in Rabbit (Cat. No. SAB4200779) was used to detect NRAS from whole extract of Human HEK-293T over-expressing NRAS. Reactivity is observed with NRAS but not with KRAS and HRAS over-expressing cells. The antibody was developed using Goat Anti-Rabbit IgG-Peroxidase (Cat. No. A0545) and a chemiluminescent substrate. Lanes 1. Negative control: HEK-293T cell extract 2. NRAS over-expressing HEK-293T cell extract 3. HRAS over-expressing HEK-293T cell extract 4. KRAS over-expressing HEK-293T cell extract
Western Blotting Whole extract of Human HEK-293T over-expressing NRAS was separated on SDS-PAGE and probed with Anti-NRAS (C-terminal) antibody produced in Rabbit (Cat. No. SAB4200779). The antibody was developed using Goat Anti-Rabbit IgG-Peroxidase (Cat. No. A0545) and a chemiluminescent substrate. Lanes 1. Antibody dilution 1:1,000 2. Antibody dilution 1:2,000 3. Antibody dilution 1:4,000 4. Antibody dilution 1:8,000 5. Antibody dilution 1:16,000 6. Antibody dilution 1:32,000 7. Antibody dilution 1:64,000 8. Antibody dilution 1:2,000 + NRAS immunizing peptide 9. positive control 1:5,000 mouse Anti-FLAG, Clone: M2 (Cat. No. F1804) 10. Negative control: without first Antibody
| antibody form | IgG fraction of antiserum |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| enhanced validation | recombinant expression Learn more about Antibody Enhanced Validation  |
| form | buffered aqueous solution |
| mol wt | predicted mol wt ~21 kDa |
| shipped in | dry ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunoblotting: 1:2,000-1:4,000 using human HEK-293T cells over-expressing NRAS protein |
| UniProt accession no. | P01111  |
| Application: | Anti-NRAS (C-terminal) antibody produced in rabbit has been used in immunoblotting. |
| Biochem/physiol Actions: | Anti-NRAS (C-terminal) antibody specifically recognizes human NRAS and does not cross-react with HRAS or KRAS. |
| Biochem/physiol Actions: | Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS) was the first melanoma oncogene to be identified. Oncogenic NRAS mutations are single base substitutions (most commonly affecting residues G12, G13, or Q61) that lead to the stabilization of GTP binding and constitutive activation of RAS and downstream signaling cascades. Abnormal NRAS activity stimulates several signaling pathways, including mitogen-activated protein kinase (MAPK/ERK), serine/threonine-protein kinase (RAFs) (ARAF, BRAF, and CRAF), phosphatidylinositol 3-kinase (PI3K) and the RAS-like protein (RAL) guanine nucleotide exchange factors (GEFs) signaling pathways. This leads to uncontrolled cell proliferation, resistance to apoptosis and thus cancer therapy potential target. NRAS mutations are present in various cancers, including melanomas, acute myeloid leukemia, colon, thyroid and lung cancers. Mutations are also implicated in hematologic malignancies, including acute lymphocytic leukemia, myelodysplastic syndrome, multiple myeloma and chronic myelomonocytic leukemia. |
| Disclaimer: | Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| General description: | Transforming protein N-Ras (NRAS), also known as GTPase NRas or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, is a member of the Ras protein family and are low molecular-weight GTPases. NRAS is mapped to human chromosome location 1p13.2 and shows ubiquitous expression. Ras proteins have highly homologous primary amino acid sequence and differ in their C-terminal region termed as hypervariable region (HVR). |
| Immunogen: | Synthetic peptide from the internal region of human NRAS protein, conjugated to KLH |
| Physical form: | Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide. |
| Preparation Note: | For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |